Table 2. Post-InO–acquired CD22... | American Society of Hematology

Table 2.

Post-InO–acquired CD22 mutations

Patient	Subtype	Relapse day	Sample day	Blast % by morphology	Blast % by MRD flow	Sum of VAF	Amino acid change	Effect	VAF
SJALL058975	DUX4-R	303	303	31	21	0.15	p.R75T	Missense	0.03
							p.N101fs	Frameshift (truncating)	0.02
							p.C529Y	Missense	0.1
SJALL058834	Hyperdiploid	185	214	80	31	0.64	p.Q116X	Nonsense (truncating)	0.07
							p.V136fs	Frameshift (truncating)	0.07
							p.L178fs	Frameshift (truncating)	0.41
							p.X848G	Stoploss (addition of 93 amino acids)	0.09
SJALL074541	ETV6::RUNX1	191	191	25	10	0.13	p.L104P	Missense	0.05
							p.R433X	Nonsense (truncating)	0.02
							p.G745fs	Frameshift (truncating)	0.06

Patient	Subtype	Relapse day	Sample day	Blast % by morphology	Blast % by MRD flow	Sum of VAF	Amino acid change	Effect	VAF
SJALL058975	DUX4-R	303	303	31	21	0.15	p.R75T	Missense	0.03
							p.N101fs	Frameshift (truncating)	0.02
							p.C529Y	Missense	0.1
SJALL058834	Hyperdiploid	185	214	80	31	0.64	p.Q116X	Nonsense (truncating)	0.07
							p.V136fs	Frameshift (truncating)	0.07
							p.L178fs	Frameshift (truncating)	0.41
							p.X848G	Stoploss (addition of 93 amino acids)	0.09
SJALL074541	ETV6::RUNX1	191	191	25	10	0.13	p.L104P	Missense	0.05
							p.R433X	Nonsense (truncating)	0.02
							p.G745fs	Frameshift (truncating)	0.06

MRD, measurable residual disease.